GlassScriptPhysician profile
Timothy Clifton
NPI 1043666514
$2,370.48
in general payments reported to CMS, 2019-2025
22 companies · $488 in 2025
The $488 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.57 · 2020: $183 · 2021: $214 · 2022: $388 · 2023: $625 · 2024: $422 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,534.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $627.98 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $354.78 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $254.76 | 2020-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $172.46 | 2020-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sanofi-Aventis U.S. LLC | $145.24 | 2024-2025 | |
| Sanofi Pasteur INC. | $145.01 | 2023-2025 | |
| Adlon Therapeutics L.P. | $133.74 | 2019-2021 | |
| Glaxosmithkline, LLC. | $103.58 | 2020-2024 | Bexsero, Pediarix |
| Pfizer INC. | $63.61 | 2020-2025 | |
| Neos Therapeutics, LP | $56.12 | 2021-2022 | |
| Seqirus USA INC | $50.97 | 2024-2025 | Flucelvax |
| Collegium Pharmaceutical, INC. | $49.38 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $45.29 | 2022 | |
| Biogen, INC. | $29.45 | 2021 | |
| Photonicare INC | $22.30 | 2025 | Otosight Middle Ear Scope |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $19.17 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $18.66 | 2024 | Flumist Quadrivalent |
| Biomarin Pharmaceutical INC. | $17.89 | 2025 | Voxzogo 1.2mg |
| Acadia Pharmaceuticals INC | $16.22 | 2025 | Daybue |
| Avion Pharmaceuticals | $15.39 | 2023 | Methylphenidate Hydrochloride |
| Ucb, INC. | $14.51 | 2024 | Nayzilam |
| Vertical Pharmaceuticals, LLC | $13.97 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Clifton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.